Literature DB >> 29724719

MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis.

Maria C Trissal1, Terrence N Wong1, Juo-Chin Yao1, Rahul Ramaswamy1, Iris Kuo1, Jack Baty2, Yaping Sun3, Gloria Jih4, Nishi Parikh4, Melissa M Berrien-Elliott1, Todd A Fehniger1, Timothy J Ley1, Ivan Maillard3,4,5, Pavan R Reddy3, Daniel C Link6.   

Abstract

Point mutations in the seed sequence of miR-142-3p are present in a subset of acute myelogenous leukemia (AML) and in several subtypes of B-cell lymphoma. Here, we show that mutations associated with AML result both in loss of miR-142-3p function and in decreased miR-142-5p expression. Mir142 loss altered the hematopoietic differentiation of multipotent hematopoietic progenitors, enhancing their myeloid potential while suppressing their lymphoid potential. During hematopoietic maturation, loss of Mir142 increased ASH1L protein expression and consequently resulted in the aberrant maintenance of Hoxa gene expression in myeloid-committed hematopoietic progenitors. Mir142 loss also enhanced the disease-initiating activity of IDH2-mutant hematopoietic cells in mice. Together these data suggest a novel model in which miR-142, through repression of ASH1L activity, plays a key role in suppressing HOXA9/A10 expression during normal myeloid differentiation. AML-associated loss-of-function mutations of MIR142 disrupt this negative signaling pathway, resulting in sustained HOXA9/A10 expression in myeloid progenitors/myeloblasts and ultimately contributing to leukemic transformation.Significance: These findings provide mechanistic insights into the role of miRNAs in leukemogenesis and hematopoietic stem cell function. Cancer Res; 78(13); 3510-21. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29724719      PMCID: PMC6030481          DOI: 10.1158/0008-5472.CAN-17-3592

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  49 in total

1.  Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo.

Authors:  C Buske; M Feuring-Buske; J Antonchuk; P Rosten; D E Hogge; C J Eaves; R K Humphries
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  MicroRNA-142 controls thymocyte proliferation.

Authors:  Alexander Mildner; Elik Chapnik; Diana Varol; Tegest Aychek; Nardi Lampl; Natalia Rivkin; Anita Bringmann; Franziska Paul; Sigalit Boura-Halfon; Yifat Segal Hayoun; Zohar Barnett-Itzhaki; Ido Amit; Eran Hornstein; Steffen Jung
Journal:  Eur J Immunol       Date:  2017-06-06       Impact factor: 5.532

3.  miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.

Authors:  Marianna Colamaio; Francesca Puca; Elvira Ragozzino; Marica Gemei; Myriam Decaussin-Petrucci; Concetta Aiello; André Uchimura Bastos; Antonella Federico; Gennaro Chiappetta; Luigi Del Vecchio; Liborio Torregrossa; Sabrina Battista; Alfredo Fusco
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

4.  Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Authors:  Anuhar Chaturvedi; Michelle Maria Araujo Cruz; Nidhi Jyotsana; Amit Sharma; Haiyang Yun; Kerstin Görlich; Martin Wichmann; Adrian Schwarzer; Matthias Preller; Felicitas Thol; Johann Meyer; Reinhard Haemmerle; Eduard A Struys; Erwin E Jansen; Ute Modlich; Zhixiong Li; Laura M Sly; Robert Geffers; Robert Lindner; Dietmar J Manstein; Ulrich Lehmann; Jürgen Krauter; Arnold Ganser; Michael Heuser
Journal:  Blood       Date:  2013-08-16       Impact factor: 22.113

5.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.

Authors:  Masato Sasaki; Christiane B Knobbe; Joshua C Munger; Evan F Lind; Dirk Brenner; Anne Brüstle; Isaac S Harris; Roxanne Holmes; Andrew Wakeham; Jillian Haight; Annick You-Ten; Wanda Y Li; Stefanie Schalm; Shinsan M Su; Carl Virtanen; Guido Reifenberger; Pamela S Ohashi; Dwayne L Barber; Maria E Figueroa; Ari Melnick; Juan-Carlos Zúñiga-Pflücker; Tak W Mak
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

6.  MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer.

Authors:  Zhe Lei; Guili Xu; Longqiang Wang; Haiping Yang; Xia Liu; Jun Zhao; Hong-Tao Zhang
Journal:  FASEB J       Date:  2014-02-20       Impact factor: 5.191

7.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

8.  miR-142 orchestrates a network of actin cytoskeleton regulators during megakaryopoiesis.

Authors:  Elik Chapnik; Natalia Rivkin; Alexander Mildner; Gilad Beck; Ronit Pasvolsky; Eyal Metzl-Raz; Yehudit Birger; Gail Amir; Itay Tirosh; Ziv Porat; Liron L Israel; Emmanuel Lellouche; Shulamit Michaeli; Jean-Paul M Lellouche; Shai Izraeli; Steffen Jung; Eran Hornstein
Journal:  Elife       Date:  2014-05-23       Impact factor: 8.140

9.  Erythrocyte survival is controlled by microRNA-142.

Authors:  Natalia Rivkin; Elik Chapnik; Alexander Mildner; Gregory Barshtein; Ziv Porat; Elena Kartvelishvily; Tali Dadosh; Yehudit Birger; Gail Amir; Saul Yedgar; Shai Izraeli; Steffen Jung; Eran Hornstein
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

10.  SomamiR 2.0: a database of cancer somatic mutations altering microRNA-ceRNA interactions.

Authors:  Anindya Bhattacharya; Yan Cui
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

View more
  15 in total

1.  Retracted Article: LncRNA ZEB2-AS1 regulates the drug resistance of acute myeloid leukemia via the miR-142-3p/INPP4B axis.

Authors:  Kai Wang; Jing Dai; Tao Liu; Qiong Wang; Yingxu Pang
Journal:  RSC Adv       Date:  2019-12-02       Impact factor: 4.036

2.  Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.

Authors:  Bin Xu; Tingting Qin; Jingcheng Yu; Thomas J Giordano; Maureen A Sartor; Ronald J Koenig
Journal:  J Biol Chem       Date:  2020-05-12       Impact factor: 5.157

3.  Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.

Authors:  David S Rogawski; Jing Deng; Hao Li; Hongzhi Miao; Dmitry Borkin; Trupta Purohit; Jiho Song; Jennifer Chase; Shuangjiang Li; Juliano Ndoj; Szymon Klossowski; EunGi Kim; Fengbiao Mao; Bo Zhou; James Ropa; Marta Z Krotoska; Zhuang Jin; Patricia Ernst; Xiaomin Feng; Gang Huang; Kenichi Nishioka; Samantha Kelly; Miao He; Bo Wen; Duxin Sun; Andrew Muntean; Yali Dou; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Nat Commun       Date:  2021-05-14       Impact factor: 14.919

4.  Pan-cancer analysis of somatic mutations in miRNA genes.

Authors:  Martyna O Urbanek-Trzeciak; Paulina Galka-Marciniak; Paulina M Nawrocka; Ewelina Kowal; Sylwia Szwec; Maciej Giefing; Piotr Kozlowski
Journal:  EBioMedicine       Date:  2020-10-07       Impact factor: 8.143

5.  MicroRNA-142 Critically Regulates Group 2 Innate Lymphoid Cell Homeostasis and Function.

Authors:  Luke B Roberts; Geraldine M Jowett; Emily Read; Tomas Zabinski; Rita Berkachy; Murray E Selkirk; Ian Jackson; Umar Niazi; Nelomi Anandagoda; Masatake Araki; Kimi Araki; Jagath Kasturiarachchi; Chela James; Tariq Enver; Rachael Nimmo; Rita Reis; Jane K Howard; Joana F Neves; Graham M Lord
Journal:  J Immunol       Date:  2021-05-21       Impact factor: 5.422

Review 6.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

Review 7.  Targeting microRNA in hematologic malignancies.

Authors:  Zhen Han; Steven T Rosen; Christiane Querfeld
Journal:  Curr Opin Oncol       Date:  2020-09       Impact factor: 3.915

Review 8.  Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.

Authors:  Cristina Panuzzo; Elisabetta Signorino; Chiara Calabrese; Muhammad Shahzad Ali; Jessica Petiti; Enrico Bracco; Daniela Cilloni
Journal:  J Clin Med       Date:  2020-03-16       Impact factor: 4.241

9.  Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial-Mesenchymal Transition and Stemness in Esophageal Carcinoma.

Authors:  Chih-Ming Huang; Chin-Sheng Huang; Tung-Nien Hsu; Mao-Suan Huang; Iat-Hang Fong; Wei-Hwa Lee; Shao-Cheng Liu
Journal:  Cells       Date:  2019-12-18       Impact factor: 6.600

10.  Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes.

Authors:  A Marshall; J Kasturiarachchi; P Datta; Y Guo; E Deltcheva; C James; J Brown; G May; N Anandagoda; I Jackson; J K Howard; E Ghazaly; S Brooks; A Khwaja; M Araki; K Araki; D Linch; G M Lord; T Enver; R Nimmo
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.